Memory Pharmaceuticals has announced that it will begin a Phase IIa clinical trial of MEM 3454 for Alzheimer's disease.

MEM 3454 was safe and well-tolerated in Phase I trials, including treatment with 450 mg dosages during the single-ascending-dose portion of the trial program. The drug was also safe and generally well-tolerated with 150 mg dosages in the multiple-ascending-dose portion of the program.